Vaccine

Registration Opens for Access Insights Conference 2025: The Only Pharma Conference Covering the Full Commercialization Spectrum

Agenda Focuses on Balancing Patient Access and Net Revenue Optimization Keynote Speaker Bill Roth Joins Industry Veterans, Practitioners, and Technologists...

Merck Manuals to Collaborate with Microsoft to Integrate Medical Information Resources into Healthcare Agent Service in Microsoft Copilot Studio

RAHWAY, N.J., April 14, 2025 /PRNewswire/ -- The Merck Manuals is pleased to announce its collaboration with Microsoft to integrate...

TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced the presentation of data yesterday highlighting...

Tonix Pharmaceuticals and Makana Therapeutics Announce Collaboration Combining Tonix’s Anti-CD40L Monoclonal Antibody (TNX-1500) with Makana’s Genetically Engineered Organs in Preclinical and Clinical Xenotransplantation Studies

ENA Respiratory Partners with University of Maryland and Leading Respiratory Disease Expert to Conduct Phase 2 Study of INNA-051 Antiviral Host Defence Enhancer

Phase 2 to evaluate safety, tolerability and efficacy of INNA-051 in the prevention of illness due to viral respiratory infectionsStudy...

Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson’s Disease

HUNTSVILLE, Ala., April 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing...

Rapid Dose Therapeutics Provides Update on the Clinical Trial Development and the Commitment to NFL Funded Cannabinoid Research

Burlington, Ontario--(Newsfile Corp. - April 8, 2025) -  Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company"), a Canadian biotech...

Teva and Samsung Bioepis Announce Biosimilar EPYSQLI® (eculizumab-aagh) Injection Now Available in the United States

EPYSQLI® (eculizumab-aagh) is now available to patients living with difficult-to-treat rare diseases like paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome...

error: Content is protected !!